Aldeyra builds case for troubled dry eye drug reproxalap

Aldeyra builds case for troubled dry eye drug reproxalap

Source: 
Pharmaforum
snippet: 

Prospects for Aldeyra’s dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn’t giving up and has new data showing an improvement over Novartis rival therapy Xiidra.